RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

24 أبريل 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

16 أبريل 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing

01 أبريل 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

25 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

11 مارس 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences

06 مارس 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

22 فبراير 2024 07:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update

22 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 فبراير 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

07 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024

31 يناير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

12 يناير 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640

04 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates

04 يناير 2024 06:58:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

15 ديسمبر 2023 16:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023

13 ديسمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event

06 ديسمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 نوفمبر 2023 16:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update

07 نوفمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)

02 نوفمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire